Femasys (FEMY) said Friday that it received a new US patent covering FemBloc, its permanent, non-surgical birth control device for women.
The company said the patent, valid until at least 2039, supports Femasys' intellectual property protection for FemBloc as it progresses through clinical trials.
Femasys plans to apply for more patents for FemBloc and other products, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments